Dr.Syed Sibtain ul Hassan

25/11/2025

24/11/2025

Grateful to conduct a Diabetes Day Camp at Mughal Eye Hospital, where we screened 300+ patients for BSR and HbA1c.
Early detection, timely intervention, and patient education remain our strongest tools against diabetes.
Together, we move towards a healthier community. 💙

23/11/2025

My first time attending the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting was fantastic. It is so inspiring to see so many people working together to achieve a common goal: a better future for those impacted by liver conditions.

18/11/2025

Omar Hospital & Cardiac Centre

18/11/2025

Omar Hospital & Cardiac Centre

16/11/2025

15/11/2025

A major development from The Liver Meeting (AASLD 2025): Wegovy (semaglutide) continues to show strong results in MASH, with high rates of steatohepatitis resolution and meaningful fibrosis improvement. These findings mark a major shift in how we approach metabolic liver disease—bringing us closer to disease-modifying treatment options for patients with F2–F3 fibrosis.
Proud to witness this new chapter in hepatology and the evolving role of GLP-1 therapies in liver care.

ESSENCE Trial highlights: Semaglutide (Wegovy) shows strong improvement in MASH — higher rates of disease resolution and fibrosis reversal. A major step forward in metabolic liver disease care.

15/11/2025

Gaining new insights at AASLD TLM25 — the New Era in MASH session highlighted real-world experience after the FDA approval of Resmetirom, along with exciting new therapies now progressing through Phase 3.
A remarkable time in liver disease innovation.